SC
OTLK icon

Scotia Capital’s Outlook Therapeutics OTLK Stock Holding History

Scotia Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,989
Closed -$117K – 965
2025
Q4 		$117K Hold
73,989
– – ﹤0.01% 866
2025
Q3 		$78.4K Hold
73,989
– – ﹤0.01% 887
2025
Q2 		$118K Sell
73,989
-50
-0.1% -$80 ﹤0.01% 822
2025
Q1 		$90.3K Buy
74,039
+50
+0.1% +$88 ﹤0.01% 814
2024
Q4 		$140K Buy
73,989
+41,023
+124% +$169K ﹤0.01% 809
2024
Q3 		$176K Hold
32,966
– – ﹤0.01% 783
2024
Q2 		$243K Buy
32,966
+9,271
+39% +$74.4K ﹤0.01% 722
2024
Q1 		$283K Buy
23,695
+9,491
+67% +$76.7K ﹤0.01% 700
2023
Q4 		$112K Sell
14,204
-2,718
-16% -$23K ﹤0.01% 762
2023
Q3 		$74.8K Buy
16,922
+13,673
+421% +$303K ﹤0.01% 743
2023
Q2 		$113K Buy
+3,249
New +$88.6K ﹤0.01% 746

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Scotia Capital's OTLK Position: Q1 2026 in Review

Scotia Capital sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 73,989 shares — an estimated $117K sold.

Scotia Capital first reported a position in OTLK in Q2 2023 and held it in 11 quarters. The position peaked at $283K in Q1 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Scotia Capital reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Scotia Capital sold 73,989 Outlook Therapeutics shares in Q1 2026, an estimated $117K.
  • Scotia Capital first reported a position in Outlook Therapeutics in Q2 2023 and held it in 11 quarters.
  • Scotia Capital's Outlook Therapeutics position peaked at $283K in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.